{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:17Z","timestamp":1791492677680,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["Study 222730"],"award-info":[{"award-number":["Study 222730"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["223559"],"award-info":[{"award-number":["223559"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.105607","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:46:40Z","timestamp":1788796000000},"page":"105607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BEHOLD-1 and -2: phase 1\/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-5890","authenticated-orcid":false,"given":"Stephanie","family":"Lheureux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-3256","authenticated-orcid":false,"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Baka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Kowalyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-0917","authenticated-orcid":false,"given":"Tim","family":"Schutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-9887","authenticated-orcid":false,"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriina","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Liu Burstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes G.J.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8675-0018","authenticated-orcid":false,"given":"Valentina","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela A.","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6495-022X","authenticated-orcid":false,"given":"Morrys","family":"Kaisermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijgc.2026.105607_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36469\/jheor.2023.87853","article-title":"Treatment patterns and outcomes among patients with advanced or recurrent endometrial cancer initiating first-line therapy in the United States","volume":"10","author":"Coleman","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"issue":"10177","key":"10.1016\/j.ijgc.2026.105607_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ijgc.2026.105607_bib5","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.3390\/cancers16142519","article-title":"B7H4 role in solid cancers: a review of the literature","volume":"16","author":"Dawidowicz","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijgc.2026.105607_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2026.05.028","article-title":"Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure","volume":"210","author":"Lee","year":"2026","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.105607_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0326691","article-title":"SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles","volume":"20","author":"Zhang","year":"2025","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ijgc.2026.105607_bib8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/cancers17060958","article-title":"Opportunities and challenges in antibody\u2013drug conjugates for cancer therapy: a New Era for cancer treatment","volume":"17","author":"Buyukgolcigezli","year":"2025","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ijgc.2026.105607_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.105607_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2026.105607_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ijgc.2026.105607_bib12","doi-asserted-by":"crossref","unstructured":"Wu J, Zhang J, Li H, et al. First-in-human\/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors. Paper presented at: ESMO 2023; 2023; Madrid, Spain. Abstract 381O.","DOI":"10.1016\/j.annonc.2023.09.558"},{"issue":"52","key":"10.1016\/j.ijgc.2026.105607_bib13","doi-asserted-by":"crossref","first-page":"S673","DOI":"10.1016\/j.annonc.2025.08.1709","article-title":"1069MO HS-20089 in patients with platinum-resistant ovarian cancer: an open-label, multi-center, phase II study","volume":"36","author":"Yuan","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105607_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.103069","article-title":"Mocertatug rezetecan (a B7-H4 targeted antibody drug conjugate) in patients with heavily pre-treated platinum-sensitive ovarian cancer (PSOC): results of an open label, phase 2 study","volume":"36","author":"Yuan","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105607_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.105607_bib16","series-title":"Paper presented at: American Association for Cancer Research Annual Meeting","article-title":"A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer","author":"Porter","year":"2024"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105607_bib17","first-page":"262","article-title":"Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antib Ther"},{"issue":"5","key":"10.1016\/j.ijgc.2026.105607_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105607_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104572","article-title":"Mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, in combination with bevacizumab in patients with platinum-sensitive ovarian cancer: results from a phase 1 study","volume":"36","author":"Wang","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.105607_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1144056","article-title":"Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective","volume":"13","author":"Murphy","year":"2023","journal-title":"Front Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26011382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26011382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:41:02Z","timestamp":1791492062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26011382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"alternative-id":["S1048891X26011382"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105607","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BEHOLD-1 and -2: phase 1\/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105607"}}